Related Experiment Video
Updated: Mar 22, 2026
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Mucinous ovarian cancer: A therapeutic review
Wen Xu1, Jack Rush2, Kirsty Rickett3
1Mater Health Services, Raymond Terrace, Brisbane, QLD 4101, Australia.
Abstract:
Mucinous ovarian cancer represents approximately 3% of epithelial ovarian cancers (EOC). Despite this seemingly low prevalence, it remains a diagnostic and therapeutic conundrum that has resulted in numerous attempts to adopt novel strategies in managing this disease. Anecdotally, there has been a prevailing notion that established gold standard systemic regimens should be substituted for those utilised in cancers such as gastrointestinal (GI) malignancies; tumours that share more biological similarities than other EOC subtypes. This review summarises the plethora of small studies which have adopted this philosophy and influenced the design of the multinational GOG142 study, which was ultimately terminated due to poor accrual. To date, there is a paucity of evidence to support delivering 'GI style' chemotherapy for mucinous ovarian cancer over and above carboplatin-paclitaxel doublet therapy. Hence there is an urge to develop studies focused on targeted therapeutic agents driven by refined mutational analysis and conducted within the context of harmonised international collaborations.
Insights
Mucinous ovarian cancer (MOC) management is challenging. Current evidence does not support using gastrointestinal (GI) chemotherapy over standard carboplatin-paclitaxel for MOC.
Area of Science:
- Oncology
- Gynecologic Oncology
- Cancer Therapeutics
Background:
- Mucinous ovarian cancer (MOC) is a rare subtype of epithelial ovarian cancer (EOC).
- MOC presents unique diagnostic and therapeutic challenges.
- There is ongoing debate regarding optimal systemic chemotherapy regimens for MOC.
Purpose of the Study:
- To review existing studies on alternative chemotherapy strategies for MOC.
- To evaluate the evidence for using gastrointestinal (GI) cancer-inspired regimens in MOC.
- To highlight the need for novel therapeutic approaches in MOC management.
Main Methods:
- Systematic review of small studies investigating non-standard chemotherapy for MOC.
- Analysis of anecdotal evidence and the rationale behind 'GI-style' chemotherapy adoption.
- Examination of the GOG142 study and reasons for its termination.
Main Results:
- Limited evidence supports 'GI-style' chemotherapy for MOC compared to standard carboplatin-paclitaxel.
- Previous studies and the GOG142 trial have not substantiated the efficacy of GI-inspired regimens.
- Carboplatin-paclitaxel remains the established standard for MOC treatment.
Conclusions:
- Current evidence does not support substituting standard chemotherapy with 'GI-style' regimens for MOC.
- Further research is needed to identify effective targeted therapies for MOC.
- International collaborations and refined mutational analysis are crucial for future MOC studies.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers